{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:39:39Z","timestamp":1780047579025,"version":"3.53.1"},"reference-count":256,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Serious vision loss occurs in patients affected by chronically raised intraocular pressure (IOP), a characteristic of many forms of glaucoma where damage to the optic nerve components causes progressive degeneration of retinal and brain neurons involved in visual perception. While many risk factors abound and have been validated for this glaucomatous optic neuropathy (GON), the major one is ocular hypertension (OHT), which results from the accumulation of excess aqueous humor (AQH) fluid in the anterior chamber of the eye. Millions around the world suffer from this asymptomatic and progressive degenerative eye disease. Since clinical evidence has revealed a strong correlation between the reduction in elevated IOP\/OHT and GON progression, many drugs, devices, and surgical techniques have been developed to lower and control IOP. The constant quest for new pharmaceuticals and other modalities with superior therapeutic indices has recently yielded health authority-approved novel drugs with unique pharmacological signatures and mechanism(s) of action and AQH drainage microdevices for effectively and durably treating OHT. A unique nitric oxide-donating conjugate of latanoprost, an FP-receptor prostaglandin (PG; latanoprostene bunod), new rho kinase inhibitors (ripasudil; netarsudil), a novel non-PG EP2-receptor-selective agonist (omidenepag isopropyl), and a form of FP-receptor PG in a slow-release intracameral implant (Durysta) represent the additions to the pharmaceutical toolchest to mitigate the ravages of OHT. Despite these advances, early diagnosis of OHT and glaucoma still lags behind and would benefit from further concerted effort and attention.<\/jats:p>","DOI":"10.3390\/ph16060791","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:18:43Z","timestamp":1685204323000},"page":"791","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients"],"prefix":"10.3390","volume":"16","author":[{"given":"Najam A.","family":"Sharif","sequence":"first","affiliation":[{"name":"Eye-APC Duke-NUS Medical School, Singapore 169856, Singapore"},{"name":"Singapore Eye Research Institute, Singapore 169856, Singapore"},{"name":"Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, TX 76107, USA"},{"name":"Department of Pharmacy Sciences, Creighton University, Omaha, NE 68178, USA"},{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA"},{"name":"Imperial College of Science and Technology, St. Mary\u2019s Campus, London SW7 2BX, UK"},{"name":"Institute of Ophthalmology, University College London, London WC1E 6BT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"ref_1","unstructured":"WHO (2022, December 02). Blindness and Vision Impairment. Fact Sheets. WHO Priority Eye Diseases. Available online: https:\/\/www.who.int\/blindness\/causes\/priority\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The Lancet global health commission on global eye health: Vision beyond","volume":"9","author":"Burton","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e053805","DOI":"10.1136\/bmjopen-2021-053805","article-title":"Time trends, associations and prevalence of blindness and vision loss due to glaucoma: An analysis of observational data from the Global Burden of Disease Study 2017","volume":"12","author":"Sun","year":"2022","journal-title":"BMJ Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: A review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"729249","DOI":"10.3389\/fphar.2021.729249","article-title":"Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies","volume":"12","author":"Sharif","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_8","unstructured":"(2021). European Glaucoma Society terminology and guidelines for glaucoma. Br. J. Ophthalmol., 105, 1\u2013169."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41433-018-0278-x","article-title":"Acute primary angle closure-treatment strategies, evidence and economic considerations","volume":"33","author":"Chan","year":"2019","journal-title":"Eye"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/2008-322X.183914","article-title":"Update on normal tension glaucoma","volume":"11","author":"Mallick","year":"2016","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Collaborative Normal-Tension Glaucoma Study Group (1998). Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol., 126, 487\u2013497.","DOI":"10.1016\/S0002-9394(98)00223-2"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Collaborative Normal-Tension Glaucoma Study Group (1998). The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol., 126, 498\u2013505.","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"(2000). AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol., 130, 429\u2013440.","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archopht.119.6.813","article-title":"Clinical factors associated with progression of glaucomatous optic disc damage in treated patients","volume":"119","author":"Tezel","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ophtha.2007.03.016","article-title":"Predictors of long-term progression in the early manifest glaucoma trial","volume":"114","author":"Leske","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ophtha.2006.07.060","article-title":"Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial","volume":"114","author":"Bengtsson","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial","volume":"385","author":"Crabb","year":"2015","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.ophtha.2010.08.049","article-title":"Reversal of retinal ganglion cell dysfunction after surgical reduction of intraocular pressure","volume":"117","author":"Sehi","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ophtha.2012.08.047","article-title":"Reversal of lamina cribrosa displacement after intraocular pressure reduction in open-angle glaucoma","volume":"120","author":"Lee","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/1570159X15666170915142727","article-title":"Novel therapeutics in glaucoma management","volume":"16","author":"Bucolo","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/14728214.2022.2110240","article-title":"Emerging drugs for the treatment of glaucoma: A review of phase II & III trials","volume":"27","author":"Kaplan","year":"2022","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.exer.2003.09.021","article-title":"The ins and outs of aqueous humor secretion","volume":"78","author":"Civan","year":"2004","journal-title":"Exp. Eye Res."},{"key":"ref_27","first-page":"100897","article-title":"Normal and glaucomatous outflow regulation","volume":"11","author":"Acott","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.preteyeres.2016.12.004","article-title":"Aqueous outflow\u2014A continuum from trabecular meshwork to episcleral veins","volume":"57","author":"Carreon","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_29","first-page":"9","article-title":"The trabecular meshwork: A basic review of form and function","volume":"2","author":"Acott","year":"2014","journal-title":"J. Ocul. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jfo.2020.05.002","article-title":"The trabecular meshwork: Structure, function and clinical implications. A review of the literature","volume":"43","author":"Buffault","year":"2020","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1073\/pnas.2001250117","article-title":"Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis","volume":"117","author":"Yan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12856","DOI":"10.1073\/pnas.2001896117","article-title":"Molecular taxonomy of human ocular outflow tissues defined by single-cell transcriptomics","volume":"117","author":"Patel","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13876","DOI":"10.1073\/pnas.1410602111","article-title":"Altered mechanobiology of Schlemm\u2019s canal endothelial cells in glaucoma","volume":"111","author":"Overby","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.preteyeres.2014.08.002","article-title":"Biomechanics of Schlemm\u2019s canal endothelium and intraocular pressure reduction","volume":"44","author":"Stamer","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"816","DOI":"10.18240\/ijo.2020.05.18","article-title":"Progress in the basic and clinical research on the Schlemm\u2019s canal","volume":"13","author":"Wang","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1111\/aos.15027","article-title":"Schlemm\u2019s canal: The outflow \u2018vessel\u2019","volume":"100","author":"Lewczuk","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1350-9462(99)00015-4","article-title":"The regulation of trabecular meshwork and ciliary muscle contractility","volume":"19","author":"Wiederholt","year":"2000","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_38","first-page":"170","article-title":"Intraocular pressure fluctuation: Is it important?","volume":"3","author":"Kim","year":"2018","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/02713683.2019.1629594","article-title":"Cyclic pattern of intraocular pressure (IOP) and transient IOP fluctuations in nonhuman primates measured with continuous wireless telemetry","volume":"44","author":"Jasien","year":"2018","journal-title":"Curr. Eye Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0161-6420(84)34248-8","article-title":"Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals","volume":"91","author":"Alvarado","year":"1984","journal-title":"Ophthalmology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/eye.1987.38","article-title":"Age-related depletion of the cell population in the human trabecular meshwork","volume":"1","author":"Grierson","year":"1987","journal-title":"Eye"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ceo.14027","article-title":"Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork\u2014A review","volume":"50","author":"Keller","year":"2022","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1167\/iovs.16-19610","article-title":"Expression of mutant myocilin induces abnormal intracellular accumulation of selected extracellular matrix proteins in the trabecular meshwork","volume":"57","author":"Kasetti","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14951","DOI":"10.1038\/s41598-017-14938-0","article-title":"Increased synthesis and deposition of extracellular matrix proteins leads to endoplasmic reticulum stress in the trabecular meshwork","volume":"7","author":"Kasetti","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.61.10.41","article-title":"Crosslinked extracellular matrix stiffens human trabecular meshwork cells via dysregulating \u03b2-catenin and YAP\/TAZ signaling pathways","volume":"61","author":"Yemanyi","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1167\/iovs.17-22175","article-title":"Estimating human trabecular meshwork stiffness by numerical modeling and advanced OCT imaging","volume":"58","author":"Wang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exer.2016.08.022","article-title":"A single gene connects stiffness in glaucoma and the vascular system","volume":"158","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15362","DOI":"10.18632\/oncotarget.3798","article-title":"The intrinsic stiffness of human trabecular meshwork cells increases with senescence","volume":"6","author":"Morgan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.exer.2017.02.010","article-title":"Cross-linked actin networks (CLANs) in glaucoma","volume":"159","author":"Bermudez","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2022461118","DOI":"10.1073\/pnas.2022461118","article-title":"Impaired TRPV4-eNOS signaling in trabecular meshwork elevates intraocular pressure in glaucoma","volume":"118","author":"Patel","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"C1013","DOI":"10.1152\/ajpcell.00599.2020","article-title":"TRPV4-Rho signaling drives cytoskeletal and focal adhesion remodeling in trabecular meshwork cells","volume":"320","author":"Lakk","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"30583","DOI":"10.1038\/srep30583","article-title":"TRPV4 regulates calcium homeostasis, cytoskeletal remodeling, conventional outflow and intraocular pressure in the mammalian eye","volume":"6","author":"Ryskamp","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1113\/JP281011","article-title":"Piezo1 channels mediate trabecular meshwork mechanotransduction and promote aqueous fluid outflow","volume":"599","author":"Yarishkin","year":"2021","journal-title":"J. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1167\/iovs.08-3127","article-title":"Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel","volume":"50","author":"Dismuke","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1167\/iovs.09-5072","article-title":"Endogenous regulation of human Schlemm\u2019s canal cell volume by nitric oxide signaling","volume":"51","author":"Ellis","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00061198-199300230-00011","article-title":"Nitric oxide and nitrovasodilators in the eye: Implications for ocular physiology and glaucoma","volume":"2","author":"Nathanson","year":"1993","journal-title":"J. Glaucoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archopht.123.4.458","article-title":"Oxidative DNA damage in the human trabecular meshwork: Clinical correlation in patients with primary open-angle glaucoma","volume":"123","author":"Pascotto","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1167\/iovs.08-2192","article-title":"Mitochondrial defects and dysfunction in calcium regulation in glaucomatous trabecular meshwork cells","volume":"49","author":"He","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.18632\/aging.202677","article-title":"Activation of ATF4 triggers trabecular meshwork cell dysfunction and apoptosis in POAG","volume":"13","author":"Ying","year":"2021","journal-title":"Aging"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Izzotti, A., Longobardi, M., Cartiglia, C., and Sacc\u00e0, S.C. (2011). Mitochondrial damage in the trabecular meshwork occurs only in primary open-angle glaucoma and in pseudoexfoliative glaucoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014567"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1167\/iovs.16-19734","article-title":"Aberrant collagen composition of the trabecular meshwork results in reduced aqueous humor drainage and elevated IOP in MMP-9 Null Mice","volume":"57","author":"Andries","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/1673-5374.245465","article-title":"Neuroinflammation as a target for glaucoma therapy","volume":"14","author":"Adornetto","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Vernazza, S., Tirendi, S., Bassi, A.M., Raverso, C.E., and Sacc\u00e0, S.C. (2020). Neuroinflammation in primary open-angle glaucoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103172"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"a017269","DOI":"10.1101\/cshperspect.a017269","article-title":"The complex role of neuroinflammation in glaucoma","volume":"4","author":"Soto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12974-015-0399-0","article-title":"Early pro-inflammatory cytokine elevations in the DBA\/2J mouse model of glaucoma","volume":"12","author":"Wilson","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1167\/iovs.11-8152","article-title":"Neurodegenerative and inflammatory pathway components linked to TNF-alpha\/TNFR1 signaling in the glaucomatous human retina","volume":"52","author":"Yang","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/eye.2017.241","article-title":"Inflammasomes, the eye and anti-inflammasome therapy","volume":"32","author":"Yerramothu","year":"2018","journal-title":"Eye"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.exer.2005.07.013","article-title":"The emerging role of proteases in retinal ganglion cell death","volume":"82","author":"Chintala","year":"2006","journal-title":"Exp. Eye Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1073\/pnas.1402819111","article-title":"Caspase-8 promotes NLRP1\/NLRP3 inflammasome activation and IL-1\u03b2 production in acute glaucoma","volume":"111","author":"Chi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13041-020-00603-7","article-title":"Ocular hypertension suppresses homeostatic gene expression in optic nerve head microglia of DBA\/2\u2009J mice","volume":"13","author":"Tribble","year":"2020","journal-title":"Mol. Brain"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.preteyeres.2004.06.001","article-title":"The optic nerve head as a biomechanical structure; a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage","volume":"24","author":"Burgoyne","year":"2005","journal-title":"Prog. Retinal Eye Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.exer.2010.08.004","article-title":"Glaucomatous cupping of the lamina cribrosa: A review of the evidence for active progressive remodeling as a mechanism","volume":"93","author":"Downs","year":"2011","journal-title":"Exp. Eye Res."},{"key":"ref_73","first-page":"1","article-title":"Correlation of lamina cribosa and standard automated perimeter findings in glaucoma and non-glaucoma patients","volume":"2","author":"Daguman","year":"2018","journal-title":"J. Ophthal. Studies"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.15-18193","article-title":"Effects of peripapillary scleral stiffening on the deformation of the lamina cribrosa","volume":"57","author":"Coudrillier","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11910-018-0831-9","article-title":"Intracranial and intraocular pressure at the lamina cribrosa: Gradient effects","volume":"18","author":"Eklund","year":"2018","journal-title":"Curr. Neurol. NeuroSci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1167\/iovs.15-18016","article-title":"Glaucoma and the role of cerebrospinal fluid dynamics","volume":"56","author":"Wostyn","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1167\/iovs.13-12327","article-title":"Torsion of the optic nerve head is a prominent feature of normal-tension glaucoma","volume":"2015","author":"Park","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.neuro.051508.135728","article-title":"Under pressure: Cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy","volume":"35","author":"Nickells","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10792-017-0795-9","article-title":"Pathophysiology of primary open-angle glaucoma from a neuroinflammatory and neurotoxicity perspective: A review of the literature","volume":"39","author":"Evangelho","year":"2019","journal-title":"Int. Ophthalmol."},{"key":"ref_80","first-page":"273","article-title":"Impaired axonal transport in glaucoma","volume":"41","author":"Fahy","year":"2016","journal-title":"Curr. Eye Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.06.006","article-title":"Assessment of retinal ganglion cell damage in glaucomatous optic neuropathy: Axon transport, injury and soma loss","volume":"141","author":"Nuschke","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/glia.22825","article-title":"An energy theory of glaucoma","volume":"63","author":"Li","year":"2015","journal-title":"Glia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2016.04.032","article-title":"Glaucoma: Focus on mitochondria in relation to pathogenesis and neuroprotection","volume":"787","author":"Osborne","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Eells, J.T. (2019). Mitochondrial dysfunction in the aging retina. Biology, 8.","DOI":"10.3390\/biology8020031"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13024-016-0089-0","article-title":"C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia\/reperfusion injury","volume":"11","author":"Silverman","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1167\/iovs.05-0830","article-title":"Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes","volume":"47","author":"Stasi","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1038\/cddis.2011.117","article-title":"A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics","volume":"2","author":"Nguyen","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_88","first-page":"1182","article-title":"Oxidative stress, mitochondrial dysfunction and calcium overload in human lamina cribrosa cells from glaucoma donors","volume":"17","author":"McElnea","year":"2011","journal-title":"Mol. Vis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-020-00400-9","article-title":"CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma","volume":"15","author":"Maddineni","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.12659\/MSM.890548","article-title":"Selected autoantibodies and normal-tension glaucoma","volume":"20","author":"Skonieczna","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-neuro-071714-034120","article-title":"The types of retinal ganglion cells: Current status and implications for neuronal classification","volume":"38","author":"Sanes","year":"2015","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1167\/iovs.04-0832","article-title":"Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix","volume":"46","author":"Guo","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1111\/j.1460-9568.2007.05528.x","article-title":"Acute retinal ganglion cell injury caused by intraocular pressure spikes is mediated by endogenous extracellular ATP","volume":"25","author":"Resta","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9240","DOI":"10.1523\/JNEUROSCI.0940-16.2016","article-title":"Selective vulnerability of specific retinal ganglion cell types and synapses after transient ocular hypertension","volume":"36","author":"Ou","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.exer.2016.06.006","article-title":"Who\u2019s lost first? Susceptibility of retinal ganglion cell types in experimental glaucoma","volume":"158","author":"Ou","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/s41598-020-60558-6","article-title":"Endothelin-1 mediated decrease in mitochondrial gene expression and bioenergetics contribute to neurodegeneration of retinal ganglion cells","volume":"10","author":"Chaphalkar","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fncel.2019.00426","article-title":"Early-stage ocular hypertension alters retinal ganglion cell synaptic transmission in the visual thalamus","volume":"13","author":"Bhandari","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/ejn.12710","article-title":"Tumor necrosis factor-alpha mediates activation of NF-\u03baB and JNK signaling cascades in retinal ganglion cells and astrocytes in opposite ways","volume":"40","author":"Dvoriantchikova","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1167\/iovs.10-5289","article-title":"Oxidative stress and the regulation of complement activation in human glaucoma","volume":"51","author":"Tezel","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.exer.2015.11.016","article-title":"Early astrocyte redistribution in the optic nerve precedes axonopathy in the DBA\/2J mouse model of glaucoma","volume":"150","author":"Cooper","year":"2016","journal-title":"Exp. Eye Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000267739","article-title":"Evidence of constriction of optic axons at the lamina cribrosa in the normotensive eye in humans and other mammals","volume":"127","author":"Hollander","year":"1995","journal-title":"Ophthalmic Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1167\/iovs.09-3814","article-title":"Functional changes in the retina during and after acute intraocular pressure elevation in mice","volume":"50","author":"Kong","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1167\/iovs.10-5284","article-title":"Microglial activation in the visual pathway in experimental glaucoma: Spatiotemporal characterization and correlation with axonal injury","volume":"51","author":"Ebneter","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archopht.124.6.853","article-title":"Visual field defects and retinal ganglion cell losses in patients with glaucoma","volume":"124","author":"Harwerth","year":"2006","journal-title":"Arch Ophthalmol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41433-019-0484-1","article-title":"Relationship between intraocular pressure and retinal nerve fibre thickness loss in a monkey model of chronic ocular hypertension","volume":"33","author":"Tu","year":"2019","journal-title":"Eye"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.ophtha.2014.06.035","article-title":"Optic nerve head deformation in glaucoma: The temporal relationship between optic nerve head surface depression and retinal nerve fiber layer thinning","volume":"121","author":"Xu","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.4103\/1673-5374.235017","article-title":"Glaucomatous optic neuropathy treatment options: The promise of novel therapeutics, techniques and tools to help preserve vision","volume":"13","author":"Sharif","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ophtha.2007.08.012","article-title":"Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma","volume":"115","author":"Medeiros","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_109","first-page":"3216","article-title":"Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma","volume":"42","author":"Yucel","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.exer.2006.09.013","article-title":"Chronic ocular hypertension induces dendrite pathology in the lateral geniculate nucleus of the brain","volume":"84","author":"Gupta","year":"2007","journal-title":"Exp. Eye Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"14168","DOI":"10.1038\/s41598-019-50793-x","article-title":"Widespread brain reorganization perturbs visuomotor coordination in early glaucoma","volume":"9","author":"Trivedi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"626056","DOI":"10.3389\/fncel.2020.626056","article-title":"Neuronal and synaptic plasticity in the visual thalamus in mouse models of glaucoma","volume":"14","author":"Monaco","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"108815","DOI":"10.1016\/j.abb.2021.108815","article-title":"Mitochondrial function is impaired in the primary visual cortex in an experimental glaucoma model","volume":"701","author":"Reides","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Yu, L., Xie, L., Dai, C., Liang, M., Zhao, L., Yin, X., and Wang, J. (2015). Progressive thinning of visual cortex in primary open-angle glaucoma of varying severity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121960"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/eye.2015.244","article-title":"A view on glaucoma\u2014Are we seeing it clearly?","volume":"30","author":"Crabb","year":"2016","journal-title":"Eye"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"109415","DOI":"10.1016\/j.exer.2023.109415","article-title":"FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma","volume":"229","author":"Sharif","year":"2023","journal-title":"Exp. Eye Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bph.14327","article-title":"Discovery, characterization and clinical utility of prostaglandin agonists for treatment of glaucoma","volume":"176","author":"Klimko","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","article-title":"Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: Advantages in clinical practice","volume":"15","author":"Hollo","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: Pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/bs.pbr.2015.06.011","article-title":"Emerging surgical therapy in the treatment of glaucoma","volume":"221","author":"Nardi","year":"2015","journal-title":"Prog. Brain Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ophtha.2019.04.034","article-title":"A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: The COMPARE Study","volume":"127","author":"Ahmed","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cts.12660","article-title":"Translating minimally invasive glaucoma surgery devices","volume":"13","author":"Lee","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","article-title":"Laser in glaucoma and ocular hypertension (LiGHT) trial: Six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension","volume":"130","author":"Gazzard","year":"2023","journal-title":"Ophthalmology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The most common barriers to glaucoma medication adherence","volume":"122","author":"Robin","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","article-title":"Side effects associated with prostaglandin analog therapy","volume":"53","author":"Alm","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e26724","DOI":"10.1097\/MD.0000000000026724","article-title":"Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up","volume":"100","author":"Yeh","year":"2021","journal-title":"Medicine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"42","DOI":"10.21926\/obm.neurobiol.2201116","article-title":"Neuropathology and therapeutics addressing glaucoma, a prevalent sight threatening retina-optic nerve-brain disease","volume":"6","author":"Sharif","year":"2022","journal-title":"OBM Neurobiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/jop.2017.0125","article-title":"iDrugs and iDevices discovery and development\u2014Preclinical assays, techniques and animal model studies for ocular hypotensives and neuroprotectants","volume":"34","author":"Sharif","year":"2018","journal-title":"J. Ocular. Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","article-title":"Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research","volume":"158","author":"Rao","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_130","first-page":"000233","article-title":"Rho kinase inhibitor utility for glaucoma and optic neuropathy treatment: Enzymic activity, IOP-lowering and neuroprotection perspectives","volume":"7","author":"Sharif","year":"2022","journal-title":"Open Access J. Ophthalmol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1167\/iovs.10-6241","article-title":"Effect of elevated intracellular cAMP on actomyosin contraction in bovine trabecular meshwork cells","volume":"52","author":"Ramachandran","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_132","first-page":"1877","article-title":"Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells","volume":"17","author":"Ramachandran","year":"2011","journal-title":"Mol. Vis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.bmcl.2009.12.012","article-title":"2,3-Diaminopyrines as rho kinase inhibitors","volume":"20","author":"Henderson","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.bmcl.2014.03.017","article-title":"In vivo optimization of 2,3-diaminopyrazine Rho kinase inhibitors","volume":"24","author":"Chen","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/IJG.0b013e318241b83c","article-title":"Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma","volume":"21","author":"Goldhagen","year":"2012","journal-title":"J. Glaucoma"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1038\/s41598-020-66928-4","article-title":"Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study","volume":"10","author":"Futakuchi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: A report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","article-title":"Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension","volume":"29","author":"Singh","year":"2020","journal-title":"J. Glaucoma"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/IJG.0000000000002124","article-title":"Partial stenosis and complete punctal closure following topical netarsudil use for glaucoma","volume":"31","author":"Rashad","year":"2022","journal-title":"J. Glaucoma"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","article-title":"Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study","volume":"226","author":"Sit","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","article-title":"Once-Daily Netarsudil\/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study","volume":"2","author":"Walters","year":"2019","journal-title":"Ophthalmol Glaucoma."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1167\/iovs.16-20189","article-title":"Netarsudil increases outflow facility in human eyes through multiple mechanisms","volume":"57","author":"Ren","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pneurobio.2015.06.002","article-title":"Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics","volume":"131","author":"Stalmans","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.expneurol.2007.02.002","article-title":"A novel rock inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats","volume":"205","author":"Sagawa","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.exer.2016.07.006","article-title":"Topical administration of a ROCK\/NET inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury","volume":"158","author":"Shaw","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e60831","DOI":"10.7554\/eLife.60831","article-title":"Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis","volume":"10","author":"Li","year":"2021","journal-title":"Elife"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajpath.2014.10.023","article-title":"RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork","volume":"185","author":"Pattabiraman","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.brainres.2007.04.013","article-title":"Fasudil, a rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons","volume":"1154","author":"Yamashita","year":"2007","journal-title":"Brain Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/02713683.2011.599106","article-title":"Effects of Y-39983, a selective rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats","volume":"36","author":"Tokushige","year":"2011","journal-title":"Curr. Eye Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/iovs.62.3.17","article-title":"NCX 667, a novel nitric oxide donor, lowers intraocular pressure in rabbits, dogs, and non-human primates and enhances TGF\u03b22-induced outflow in HTM\/HSC constructs","volume":"62","author":"Bastia","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_153","first-page":"1765","article-title":"Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye","volume":"36","author":"Nathanson","year":"1995","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_154","first-page":"1774","article-title":"Alterations of ocular nitric oxide synthase in human glaucoma","volume":"36","author":"Nathanson","year":"1995","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/jop.2016.0188","article-title":"The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: Review of nonclinical studies","volume":"34","author":"Cavet","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Kondkar, A.A., Azad, T.A., Sultan, T., Osman, E.A., Almobarak, F.A., and Al-Obeidan, S.A. (2020). Association of endothelial nitric oxide synthase (NOS3) gene polymorphisms with primary open-angle glaucoma in a Saudi cohort. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227417"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"100922","DOI":"10.1016\/j.preteyeres.2020.100922","article-title":"The vital role for nitric oxide in intraocular pressure homeostasis","volume":"83","author":"Pasquale","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_158","unstructured":"Ellis, D., Scheibler, L., and Sharif, N.A. (2017). Prostaglandin Conjugates and Derivatives for Treating Glaucoma and Ocular Hypertension. (9604949 B2), U.S. Patent."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jcp.24454","article-title":"Nitric oxide regulation of Na, K-ATPase activity in ocular ciliary epithelium involves Src family kinase","volume":"229","author":"Shahidullah","year":"2014","journal-title":"J. Cell Physiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/IJG.0000000000001904","article-title":"Two-Year Experience With Latanoprostene Bunod in Clinical Practice","volume":"30","author":"Radell","year":"2021","journal-title":"J. Glaucoma"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"109235","DOI":"10.1016\/j.exer.2022.109235","article-title":"Sympathetic activation leads to Schlemm\u2019s canal expansion via increasing vasoactive intestinal polypeptide secretion from trabecular meshwork","volume":"224","author":"Xu","year":"2022","journal-title":"Exp. Eye Res."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Roddy, G.W., Roy Chowdhury, U., Anderson, K.J., Rinkoski, T.A., Hann, C.R., Chiodo, V.A., Smith, W.C., and Fautsch, M.P. (2022). Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0269261"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ophtha.2016.01.019","article-title":"Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study","volume":"123","author":"Weinreb","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/IJG.0000000000000831","article-title":"Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings","volume":"27","author":"Weinreb","year":"2018","journal-title":"J. Glaucoma"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/cxo.12853","article-title":"Latanoprostene bunod ophthalmic solution 0.024%: A new treatment option for open-angle glaucoma and ocular hypertension","volume":"102","author":"Fingeret","year":"2019","journal-title":"Clin. Exp. Optom."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40265-018-0914-6","article-title":"Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.2147\/OPTH.S156038","article-title":"Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: Design, development, and place in therapy","volume":"12","author":"Addis","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0014-2999(01)01486-8","article-title":"Bimatoprost and its free acid are prostaglandin FP receptor agonists","volume":"432","author":"Sharif","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1167\/iovs.02-0323","article-title":"Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues","volume":"44","author":"Sharif","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/jpet.102.042556","article-title":"Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors","volume":"304","author":"Kelly","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_171","first-page":"862","article-title":"Bimatoprost, the prodrug of a prostaglandin analogue","volume":"92","author":"Camras","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/jop.2018.0095","article-title":"Dose-response of intracameral bimatoprost sustained-release implant and topical bimatoprost in lowering intraocular pressure","volume":"35","author":"Lee","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/vop.12522","article-title":"Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs","volume":"21","author":"Lee","year":"2018","journal-title":"Vet. Ophthalmol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ophtha.2016.04.026","article-title":"Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: Results of a phase II randomized controlled study","volume":"123","author":"Brandt","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","article-title":"Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2)","volume":"81","author":"Bacharach","year":"2021","journal-title":"Drugs"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40123-022-00527-6","article-title":"Single administration of intracameral bimatoprost implant 10 \u00b5g in patients with open-angle glaucoma or ocular hypertension","volume":"11","author":"Medeiros","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","article-title":"Bimatoprost implant: First approval","volume":"37","author":"Shirley","year":"2020","journal-title":"Drugs Aging"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0039-6257(02)00293-X","article-title":"Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist","volume":"47","author":"Hellberg","year":"2002","journal-title":"Surv. Ophthalmol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/jop.2004.20.489","article-title":"Molecular pharmacology of the DP\/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes","volume":"20","author":"Sharif","year":"2004","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1167\/iovs.05-1627","article-title":"The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey","volume":"47","author":"Nilsson","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exer.2011.02.015","article-title":"Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma","volume":"93","author":"Prasanna","year":"2011","journal-title":"Exp. Eye Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/02713683.2011.593725","article-title":"A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension","volume":"36","author":"Schachar","year":"2011","journal-title":"Curr. Eye Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/0192623309351724","article-title":"Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist","volume":"37","author":"Aguirre","year":"2009","journal-title":"Toxicol. Pathol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/jop.1995.11.203","article-title":"AGN 191976: A novel thromboxane A2-mimetic with ocular hypotensive properties","volume":"11","author":"Krauss","year":"1995","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1167\/iovs.14-16181","article-title":"IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys","volume":"56","author":"Yamane","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1021\/acs.jmedchem.8b00808","article-title":"Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl","volume":"61","author":"Iwamura","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1167\/iovs.17-22745","article-title":"Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent","volume":"59","author":"Kirihara","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/jop.2017.0146","article-title":"Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys","volume":"34","author":"Fuwa","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/jop.1998.14.293","article-title":"Prostaglandin-stimulated adenylyl cyclase activity via a pharmacologically-defined EP2 receptor in human NPE cells","volume":"14","author":"Crider","year":"1998","journal-title":"J. Ocular. Pharmacol. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/108076801750125658","article-title":"Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells","volume":"17","author":"Crider","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_191","first-page":"1475","article-title":"Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues","volume":"43","author":"Zenkel","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.bbrc.2005.10.051","article-title":"Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42\/44 mitogen-activated protein kinases","volume":"338","author":"Rosch","year":"2005","journal-title":"Biochem. Biophys Res. Commun."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/exer.1996.0119","article-title":"Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species","volume":"63","author":"Yousufzai","year":"1996","journal-title":"Exp. Eye Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/10807680260362678","article-title":"Production of prostaglandin E(2) by iridial melanocytes exposed to latanoprost acid, a prostaglandin F(2 alpha) analogue","volume":"18","author":"Bergh","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1038\/s41598-021-83713-z","article-title":"Mechanical stretch induces Ca(2+) influx and extracellular release of PGE2 through Piezo1 activation in trabecular meshwork cells","volume":"2021","author":"Uchida","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_196","first-page":"3195","article-title":"Prostanoid-induced relaxation of precontracted cat ciliary muscle is mediated by EP2 and DP receptors","volume":"33","author":"Chen","year":"1992","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_197","first-page":"1188","article-title":"Characterization of ciliary muscle relaxation induced by various agents in cats","volume":"36","author":"Goh","year":"1995","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1006\/exer.1996.0224","article-title":"Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle","volume":"64","author":"Krauss","year":"1997","journal-title":"Exp. Eye Res."},{"key":"ref_199","first-page":"2515","article-title":"Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide","volume":"35","author":"Wiederholt","year":"1994","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_200","first-page":"3182","article-title":"Detection of prostaglandin EP(1), EP(2), and FP receptor subtypes in human sclera","volume":"42","author":"Anthony","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"16257","DOI":"10.1038\/s41598-021-95768-z","article-title":"Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm\u2019s canal endothelial cells and ciliary muscle contraction","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Kumon, M., Fuwa, M., Shimazaki, A., Odani-Kawabata, N., Iwamura, R., Yoneda, K., and Kato, M. (2023). Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280331"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.bbamcr.2016.06.008","article-title":"Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53","volume":"1863","author":"Kalouche","year":"2016","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1167\/iovs.15-17693","article-title":"Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells","volume":"57","author":"Kalouche","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/jop.2019.0044","article-title":"Pharmacokinetics, safety, and intraocular pressure-lowering profile of omidenepag isopropyl, a selective, non-prostaglandin, prostanoid EP2 receptor agonist, in healthy Japanese and Caucasian volunteers (Phase I Study)","volume":"35","author":"Aihara","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/IJG.0000000000001221","article-title":"Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Aihara","year":"2019","journal-title":"J. Glaucoma"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","article-title":"Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: The RENGE study","volume":"65","author":"Aihara","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","article-title":"Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: The phase 3 AYAME study","volume":"220","author":"Aihara","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10384-020-00748-x","article-title":"Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-\/low-responder patients with primary open-angle glaucoma or ocular hypertension: The FUJI study","volume":"64","author":"Aihara","year":"2020","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_210","unstructured":"McLaurin, E.B., and Tepedino, M.E. (, January September). Omidenepag is Opropyl 0.002% Significantly Lowers Iop in Latanoprost Low\/Non-Responders with POAG or OHT: Phase 3 SPECTRUM 5 Study. Proceedings of the World Ophthalmology Congress, Virtual."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/OPTH.S340386","article-title":"Efficacy and patient tolerability of omidenepag isopropyl in the treatment of glaucoma and ocular hypertension","volume":"16","author":"Matsuo","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s12325-022-02069-6","article-title":"Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan","volume":"39","author":"Miki","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s12325-021-02035-8","article-title":"Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan","volume":"39","author":"Nakazawa","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/jop.2020.0071","article-title":"Additive intraocular pressure-lowering effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, combined with existing antiglaucoma agents in conscious ocular normotensive monkeys","volume":"37","author":"Fuwa","year":"2021","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0039-6257(97)80020-3","article-title":"The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color","volume":"41","author":"Wistrand","year":"1997","journal-title":"Surv. Ophthalmol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ceo.12163","article-title":"Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost","volume":"42","author":"Kucukevcilioglu","year":"2014","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_217","first-page":"e10368","article-title":"Evaluation of patterns and correlations of the degree of conjunctival hyperemia induced by omidenepag isopropyl 0.002% and ripasudil 0.4%","volume":"12","author":"Terao","year":"2020","journal-title":"Cureus"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/jop.2020.0003","article-title":"The antiglaucoma agent and EP2 receptor agonist omidenepag does not affect eyelash growth in mice","volume":"36","author":"Esaki","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajo.2021.12.011","article-title":"Periocular adverse reactions to omidenepag isopropyl","volume":"237","author":"Inoue","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"20406223221140392","DOI":"10.1177\/20406223221140392","article-title":"Current situation and progress of drugs for reducing intraocular pressure","volume":"13","author":"Liu","year":"2022","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"749858","DOI":"10.3389\/fphar.2021.749858","article-title":"Topical medication therapy for glaucoma and ocular hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/acs.jmedchem.5b00828","article-title":"Discovery of molecular therapeutics for glaucoma: Challenges, successes, and promising directions","volume":"59","author":"Donegan","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"692609","DOI":"10.1155\/2012\/692609","article-title":"Animal models of glaucoma","volume":"2012","author":"Bouhenni","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjophthalmol-2018-312724","article-title":"Recent advances in genetically modified animal models of glaucoma and their roles in drug repositioning","volume":"103","author":"Harada","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/bs.pmbts.2015.06.003","article-title":"What animal models can tell us about glaucoma","volume":"134","author":"Struebing","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1021\/acsptsci.0c00137","article-title":"Discovery to launch of anti-allergy (Emadine; Patanol\/Pataday\/Pazeo) and anti-glaucoma (Travatan; Simbrinza) ocular drugs, and generation of novel pharmacological tools such as AL-8810","volume":"3","author":"Sharif","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/jop.2019.0041","article-title":"Antiglaucoma EP2 agonists: A long road that led somewhere","volume":"35","author":"Woodward","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1021\/acsnano.9b07214","article-title":"Once daily pregabalin eye drops for management of glaucoma","volume":"13","author":"Ibrahim","year":"2019","journal-title":"ACS Nano"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1167\/iovs.17-23218","article-title":"Autotaxin\u2013lysophosphatidic acid pathway in intraocular pressure regulation and glaucoma subtypes","volume":"59","author":"Honjo","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/mt.2013.216","article-title":"In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma","volume":"22","author":"Roehl","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Pfeiffer, N., Voykov, B., Renieri, G., Bell, K., Richter, P., Weigel, M., Thieme, H., Wilhelm, B., Lorenz, K., and Feindor, M. (2017). First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-\u03b22), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188899"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"104149","DOI":"10.1016\/j.isci.2022.104149","article-title":"Long-term and potent IOP-lowering effect of I\u03baB\u03b1-siRNA in a nonhuman primate model of chronic ocular hypertension","volume":"25","author":"Sun","year":"2022","journal-title":"iScience"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddx028","article-title":"Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma","volume":"26","author":"Crosbie","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9-based treatment of myocilin associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ymthe.2019.12.012","article-title":"Gene therapy for glaucoma by ciliary body aquaporin 1 disruption using CRISPR-Cas","volume":"28","author":"Wu","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"964197","DOI":"10.3389\/fneur.2022.964197","article-title":"Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future","volume":"13","author":"Levin","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nbd.2014.07.016","article-title":"Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma","volume":"71","author":"Howell","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2017.0041","article-title":"Targets of neuroprotection in glaucoma","volume":"34","author":"He","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Boia, R., Ruzafa, N., Aires, I.D., Pereiro, X., Ambr\u00f3sio, A.F., Vecino, E., and Santiago, A.R. (2020). Neuroprotective strategies for retinal ganglion cell degeneration: Current status and challenges ahead. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072262"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/vop.12858","article-title":"Looking into the future: Gene and cell therapies for glaucoma","volume":"24","author":"Koehl","year":"2021","journal-title":"Vet. Ophthalmol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1167\/iovs.16-20672","article-title":"Restoration of aqueous humor outflow following transplantation of iPSC derived trabecular meshwork cells in a transgenic mouse model of glaucoma","volume":"58","author":"Zhu","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"101063","DOI":"10.1016\/j.preteyeres.2022.101063","article-title":"A novel glaucoma approach: Stem cell regeneration of the trabecular meshwork","volume":"90","author":"Coulon","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Zhang, J., Wu, S., Jin, Z.B., and Wang, N. (2021). Stem cell-based regeneration and restoration for retinal ganglion cell: Recent advancements and current challenges. Biomolecules, 11.","DOI":"10.3390\/biom11070987"},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Sharif, N.A. Electrical, electromagnetic, ultrasound wave therapies and electronic implants for neuronal rejuvenation, neuroprotection, axonal regeneration and IOP reduction. J. Ocul. Pharmacol. Ther., 2023. in press.","DOI":"10.1089\/jop.2022.0046"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"108444","DOI":"10.1016\/j.exer.2021.108444","article-title":"Layer-specific nanophotonic delivery of therapeutic opsin-encoding genes into retina","volume":"205","author":"Batabyal","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"101153","DOI":"10.1016\/j.preteyeres.2022.101153","article-title":"Cellular and subcellular optogenetic approaches towards neuroprotection and vision restoration","volume":"2022","author":"Wood","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"109393","DOI":"10.1016\/j.exer.2023.109393","article-title":"Phenotypic and functional characterization of aqueous humor derived extracellular vesicles","volume":"228","author":"Verta","year":"2023","journal-title":"Exp. Eye Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fnins.2017.00232","article-title":"Nicotinamide and WLDS Act Together to Prevent Neurodegeneration in Glaucoma","volume":"11","author":"Williams","year":"2017","journal-title":"Front Neurosci."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/ceo.13818","article-title":"Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial","volume":"48","author":"Hui","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/iovs.64.3.3","article-title":"24-Hour monitoring of intraocular pressure fluctuations using a contact lens sensor: Diagnostic performance for glaucoma progression","volume":"64","author":"Gaboriau","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"100976","DOI":"10.1016\/j.preteyeres.2021.100976","article-title":"Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic","volume":"86","author":"Cordeiro","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1167\/iovs.61.14.33","article-title":"Focal structure-function relationships in primary open-angle glaucoma using OCT and OCT-A measurements","volume":"61","author":"Wong","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/ICU.0000000000000552","article-title":"Artificial intelligence in glaucoma","volume":"30","author":"Zheng","year":"2019","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4103\/1673-5374.243712","article-title":"In vivo imaging of structural, metabolic and functional brain changes in glaucoma","volume":"14","author":"Kasi","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/IJG.0000000000001346","article-title":"Correlating structural and functional damage in glaucoma","volume":"28","author":"Torres","year":"2019","journal-title":"J. Glaucoma"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/6\/791\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:42:43Z","timestamp":1760125363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/6\/791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":256,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ph16060791"],"URL":"https:\/\/doi.org\/10.3390\/ph16060791","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]}}}